Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed invasive breast cancer~  * Metastatic disease~* HER2/neu-positive by immunohistochemistry (3+ by HercepTest\^™ or equivalent) OR positive for amplification by fluorescent in situ hybridization~  * Testing may be performed in the primary tumor or the metastatic site~* Received prior anthracycline or taxane as adjuvant therapy or for metastatic disease~* Measurable disease~  * At least one measurable lesion ≥ 2.0 cm by CT scan or MRI OR ≥ 1.0 cm by spiral CT scan~ * The following are considered non-measurable disease:~    * Bone lesions~   * Leptomeningeal disease~   * Ascites~   * Pleural/pericardial effusion~   * Inflammatory breast disease~   * Lymphangitis cutis/pulmonis~   * Abdominal masses that are not confirmed and followed by imaging techniques~   * Cystic lesions~* No bone metastases as the only evidence of metastasis~* Previously treated CNS metastases allowed provided disease has been stable for ≥ the past 3 months~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Female or male~Performance status~* ECOG 0-2~Life expectancy~* At least 12 weeks~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Hemoglobin ≥ 8.0 g/dL~* Platelet count ≥ 100,000/mm\^3~* No known uncontrolled coagulopathy~Hepatic~* Bilirubin ≤ 3.0 times the upper limit of normal (ULN)~* One of the following must be true:~  * AST or ALT ≤ 5 times ULN AND alkaline phosphatase normal~ * Alkaline phosphatase ≤ 5 times ULN AND AST or ALT normal~ * Alkaline phosphatase ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN~* INR ≤ 1.5 times ULN~Renal~* Calcium ≤ 11.5 mg/dL~* Creatinine ≤ 1.5 times ULN~* Creatinine clearance ≥ 30 mL/min~Cardiovascular~* LVEF ≥ 50% by MUGA or echocardiogram~* No clinically significant (i.e., active) cardiac disease~* No congestive heart failure~* No symptomatic coronary artery disease~* No myocardial infarction within the past 12 months~* No cardiac arrhythmia not controlled with medication~Gastrointestinal~* Able to take oral medication~* No lack of physical integrity of the upper gastrointestinal tract~* No clinically significant malabsorption syndrome~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 30 days after study participation~* No history of allergy or hypersensitivity to study drugs, drug product excipients, including polysorbate 80, or chemically similar agents~* No prior unanticipated severe reaction to fluoropyrimidine therapy~* No know hypersensitivity to fluorouracil~* No known dihydropyrimidine dehydrogenase deficiency~* No history of uncontrolled seizures or CNS disorders~* No clinically significant psychiatric disability that would preclude giving informed consent or study compliance~* No other serious uncontrolled infection or disease~* No other malignancy within the past 5 years except cured basal cell skin cancer, carcinoma in situ of the cervix, or contralateral breast cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Prior adjuvant trastuzumab (Herceptin\^®) allowed as adjuvant or first-line therapy for metastatic disease~* No concurrent immunotherapy~Chemotherapy~* See Disease Characteristics~* No more than 1 prior chemotherapy regimen in the advanced or metastatic (non-adjuvant) setting~* No prior continuous (≥ 24 hours) fluorouracil infusion~* No prior capecitabine~* No prior oral fluoropyrimidines (e.g., eniluracil and fluorouracil, uracil and tegafur, S1, or emitefur)~Endocrine therapy~* At least 1 day since prior hormonal therapy~* No concurrent hormonal therapy~Radiotherapy~* More than 4 weeks since prior radiotherapy to the axial skeleton (i.e., skull, spinal column, sternum, or ribs)~* No concurrent radiotherapy~Surgery~* More than 4 weeks since prior major surgery~* No prior organ allografts requiring immunosuppressive therapy~Other~* More than 4 weeks since prior investigational drugs~* No concurrent sorivudine or its chemically related analogues (e.g., brivudine)~* No concurrent allopurinol, metronidazole, or cimetidine~* No other concurrent cytotoxic agents~* No other concurrent investigational drugs~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- capecitabine + vinorelbine + trastuzumab (Type: EXPERIMENTAL): Patients receive oral capecitabine twice daily on days 1-14, vinorelbine IV over 6-10 minutes on days 1 and 8, and trastuzumab (Herceptin\^®) IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).